Publications

Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials.
Bhatt A.S., Vaduganathan M., Claggett B.L., Kulac I.J., Anand I.S., … , Gaziano T.A.
J Am Heart Assoc. 2024 Feb 23:e032279. doi: 10.1161/JAHA.123.032279. Online ahead of print.

Heart failure, investigator-reported sleep apnea and dapagliflozin: A patient-level pooled meta-analysis of DAPA-HF and DELIVER
Butt, J.H., Jering, K., de Boer, R.A., Claggett, B.L., Desai, A.S., … , McMurray J.J.V.
J Card Fail. 2023 Dec 15:S1071-9164(23)00913-2. doi: 10.1016/j.cardfail.2023.08.027. Online ahead of print.

Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
Chatur, S., Vaduganathan, M., Claggett, B.L., Mc Causland, F.R., Desai, A.S., … , Solomon S.D.
J Am Coll Cardiol. 2023 Nov 7;82(19):1854-1863. doi: 10.1016/j.jacc.2023.08.026. Epub 2023 Aug 25.

Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: The LIFE-HF model
Burger, P.M., Savarese, G., Tromp, J., Adamson, C., Jhund, P.S., … , Mosterd A.
Eur J Heart Fail. 2023 Nov;25(11):1962-1975. doi: 10.1002/ejhf.3028. Epub 2023 Sep 18.

Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER
Kondo, T., Butt, J.H., Curtain, J.P., Jhund, P.S., Docherty, K.F., … , McMurray J.J.V.
Circ Heart Fail. 2023 Dec;16(12):e010898. doi: 10.1161/CIRCHEARTFAILURE.123.010898. Epub 2023 Oct 27.

Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials
Kondo, T., Gasparyan, S.B., Jhund, P.S., Bengtsson, O., Claggett, B.L., … , McMurray, J.J.V.
NEJM Evidence. 2023 Oct 24;2(11). doi: 10.1056/EVIDoa2300042.

Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
Butt, J.H., Docherty, K.F., Kosiborod, M.N., Inzucchi, S.E., Køber, L., … , McMurray J.J.V.
JACC Heart Fail. 2023 Oct;11(10):1411-1423. doi: 10.1016/j.jchf.2023.04.016. Epub 2023 Jun 14.

Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure
Kondo, T., Wang, X., Yang, M., Jhund, P.S., Claggett, B.L., … , McMurray J.J.V.
J Am Coll Cardiol. 2023 Sep 5;82(10):1014-1026. doi: 10.1016/j.jacc.2023.05.056. Epub 2023 Aug 21.

Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HF
Chatur, S., Kondo, T., Claggett, B.L., Docherty, K., Miao, Z.M., … , Vaduganathan M.
Eur J Heart Fail. 2023 Aug;25(8):1364-1371. doi: 10.1002/ejhf.2912. Epub 2023 Jun 8.

Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure
Docherty, K.F., McDowell, K., Welsh, P., Osmanska, J., Anand, I., … , McMurray J.J.V.
J Am Coll Cardiol. 2023 Jul 11;82(2):142-157. doi: 10.1016/j.jacc.2023.05.011.

Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials
Bhatt, A.S., Kosiborod, M.N., Vaduganathan, M., Claggett, B.L., Miao, Z. M., … , Solomon S.D.
Eur J Heart Fail. 2023 Jul;25(7):981-988. doi: 10.1002/ejhf.2909. Epub 2023 Jun 7.

Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failure
Talha, K.M., Butler, J., Greene, S.J., Aggarwal, R., Anker, S.D., … , Fonarow G.C.
Eur J Heart Fail. 2023 Jul;25(7):999-1009. doi: 10.1002/ejhf.2864. Epub 2023 Apr 24.

Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER
Butt, J.H., Kondo, T., Yang, M., Jhund, P.S., Docherty, K.F., … , McMurray J.J.V.
Eur Heart J. 2023 Jun 25;44(24):2170-2183. doi: 10.1093/eurheartj/ehad276.

Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
Yeoh, S.E., Docherty, K.F., Campbell, R.T., Jhund, P.S., Hammarstedt, A., … , McMurray J.J.V.
Circulation. 2023 May 30;147(22):1670-1683. doi: 10.1161/CIRCULATIONAHA.122.063327. Epub 2023 Apr 11.

Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
Butt, J.H., Docherty, K.F., Claggett, B.L., Desai, A.S., Fang, J.C., … , McMurray J.J.V.
JACC Heart Fail. 2023 Apr;11(4):375-388. doi: 10.1016/j.jchf.2022.11.014. Epub 2023 Feb 1.

Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER
Butt, J.H., Docherty, K.F., Claggett, B.L., Desai, A.S., Petersson, M., … , McMurray J.J.V.
JAMA Cardiol. 2023 Apr 1;8(4):386-393. doi: 10.1001/jamacardio.2022.5608.

IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF
Adamson, C., Welsh, P., Docherty, K.F., de Boer, R.A., Diez, M., … , Jhund P.S.
JACC Heart Fail. 2023 Mar;11(3):291-304. doi: 10.1016/j.jchf.2022.09.004. Epub 2022 Nov 9.

Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER
Wang, X., Vaduganathan, M., Claggett, B.L., Hegde, S.M., Pabon, M., … , Lam C.S.P.
Circulation. 2023 Feb 21;147(8):624-634. doi: 10.1161/CIRCULATIONAHA.122.062832. Epub 2022 Nov 7.

Cost-effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure
Miller, R.J.H., Chew, D.S., Qin, L., Fine, N.M., Chen, J., … , McEwan P.
Eur J Heart Fail. 2023 Feb;25(2):238-247. doi: 10.1002/ejhf.2777.

Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER
Desai, A.S., Jhund, P.S., Claggett, B.L., Vaduganathan, M., Miao, Z.M., … , Solomon S.D.
JAMA Cardiol. 2022 Dec 1;7(12):1227-1234. doi: 10.1001/jamacardio.2022.3736.

Reply to ‘The 50 shades of bilirubin’. Letter regarding the article ‘Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF’
Adamson, C., Jhund, P.S., McMurray, J.J.V.
Eur J Heart Fail. 2022 Nov;24(11):2206-2207. doi: 10.1002/ejhf.2683. Epub 2022 Sep 20.

Reply to ‘Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction – lessons from clinical trials’
McDowell, K., Jhund, P.S., McMurray, J.J.V.
Eur J Heart Fail. 2022 Oct;24(10):1994. doi: 10.1002/ejhf.2686. Epub 2022 Sep 19.

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF
Adamson, C., Cowan, L.M., de Boer, R.A., Diez, M., Drożdż, J., … , Jhund P.S.
Eur J Heart Fail. 2022 Oct;24(10):1856-1868. doi: 10.1002/ejhf.2649. Epub 2022 Aug 22.

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Docherty, K.F., Welsh, P., Verma, S., De Boer, R.A., O’Meara, E., … , McMurray J.J.V.
Circulation. 2022 Sep 27;146(13):980-994. doi: 10.1161/CIRCULATIONAHA.122.060511. Epub 2022 Aug 16.

SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Vaduganathan, M., Docherty, K.F., Claggett, B.L., Jhund, P.S., de Boer, R.A., … , Solomon S.D.
Lancet. 2022 Sep 3;400(10354):757-767. doi: 10.1016/S0140-6736(22)01429-5. Epub 2022 Aug 27.

Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Jhund, P.S., Kondo, T., Butt, J.H., Docherty, K.F., Claggett, B.L., … , McMurray J.J.V.
Nat Med. 2022 Sep;28(9):1956-1964. doi: 10.1038/s41591-022-01971-4. Epub 2022 Aug 27.

Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
Adamson, C., Docherty, K.F., Heerspink, H.J.L., de Boer, R.A., Damman, K., … , McMurray J.J.V.
Circulation. 2022 Aug 9;146(6):438-449. doi: 10.1161/CIRCULATIONAHA.121.058910. Epub 2022 Apr 20.

Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF
Butt, J.H., Dewan, P., DeFilippis, E.M., Biering-Sørensen, T., Docherty, K.F., … , McMurray J.J.V.
JACC Heart Fail. 2022 Aug;10(8):543-555. doi: 10.1016/j.jchf.2022.03.009. Epub 2022 Jun 8.

Accelerated and personalized therapy for heart failure with reduced ejection fraction
Shen, L., Jhund, P.S., Docherty, K.F., Vaduganathan, M., Petrie, M.C., … , McMurray J.J.V.
Eur Heart J. 2022 Jul 14;43(27):2573-2587. doi: 10.1093/eurheartj/ehac210.

Insights into foundational therapies for heart failure with reduced ejection fraction
McMurray, J.J.V., Docherty, K.F.
Clin Cardiol. 2022 Jun;45 Suppl 1(Suppl 1):S26-S30. doi: 10.1002/clc.23847.

Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial
Butt, J.H., Dewan, P., Merkely, B., Belohlávek, J., Drożdż, J., … , McMurray J.J.V.
Ann Intern Med. 2022 Jun;175(6):820-830. doi: 10.7326/M21-4776. Epub 2022 Apr 26.

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF
McDowell, K., Welsh, P., Docherty, K.F., Morrow, D.A., Jhund, P.S., … , McMurray J.J.V.
Eur J Heart Fail. 2022 Jun;24(6):1066-1076. doi: 10.1002/ejhf.2433. Epub 2022 Feb 6.

Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial
Yeoh, S.E., Docherty, K.F., Jhund, P.S., Petrie, M.C., Inzucchi, S.E., … , McMurray J.J.V.
JACC Heart Fail. 2022 May;10(5):306-318. doi: 10.1016/j.jchf.2022.01.019. Epub 2022 Apr 6.

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Docherty, K.F., Anand, I.S., Chiang, C-E., Chopra, V.K., Desai, A.S., … , McMurray J.J.V.
JACC Asia. 2022 Mar 29;2(2):139-153. doi: 10.1016/j.jacasi.2022.02.004. eCollection 2022 Apr.

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF
Butt, J.H., Docherty, K.F., Jhund, P.S., de Boer, R.A., Böhm, M., … , Køber L.
Eur J Heart Fail. 2022 Mar;24(3):513-525. doi: 10.1002/ejhf.2381. Epub 2021 Nov 24.

Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF
Docherty, K.F., Simpson, J., Jhund, P.S., Inzucchi, S.E., Køber, L., … , McMurray J.J.V.
JACC Heart Fail. 2022 Feb;10(2):104-118. doi: 10.1016/j.jchf.2021.09.002. Epub 2022 Jan 12.

Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial
Berg, D.D., Docherty, K.F., Sattar, N., Jarolim, P., Welsh, P., … , Morrow D.A.
Circulation. 2022 Jan 18;145(3):158-169. doi: 10.1161/CIRCULATIONAHA.121.057852. Epub 2021 Nov 8.

Foundational drugs for HFrEF: the growing evidence for a rapid sequencing strategy
Docherty, K.F., McMurray, J.J.V.
Br J Cardiol. 2022 Jan 12;29(1):2. doi: 10.5837/bjc.2022.002. eCollection 2022.

Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
Docherty, K.F., Ogunniyi, M.O., Anand, I.S., Desai, A.S., Diez, M., … , McMurray J.J.V.
JACC Heart Fail. 2022 Jan;10(1):52-64. doi: 10.1016/j.jchf.2021.08.006. Epub 2021 Nov 10.

Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
Rossing, P., Inzucchi, S.E., Vart, P., Jongs, N., Docherty, K.F., … , Heerspink H.J L.
Lancet Diabetes Endocrinol. 2022 Jan;10(1):24-34. doi: 10.1016/S2213-8587(21)00295-3. Epub 2021 Nov 29.

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial
Butt, J.H., Adamson, C., Docherty, K.F., de Boer, R.A., Petrie, M.C., … , Køber L.
Circ Heart Fail. 2021 Dec;14(12):e008837. doi: 10.1161/CIRCHEARTFAILURE.121.008837. Epub 2021 Nov 22.

Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial
Docherty, K.F., Jhund, P.S., Claggett, B., Ferreira, J.P., Bengtsson, O., … , Ho D.
JAMA Cardiol. 2021 Nov 1;6(11):1298-1305. doi: 10.1001/jamacardio.2021.2632.

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
Adamson, C., Jhund, P.S., Docherty, K.F., Bělohlávek, J., Chiang, C‐E., … , McMurray J.J.V.
Eur J Heart Fail. 2021 Oct;23(10):1662-1672. doi: 10.1002/ejhf.2308. Epub 2021 Jul 29.

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
Curtain, J.P., Docherty, K.F., Jhund, P.S., Petrie, M.C., Inzucchi, S.E., … , McMurray J.J.V.
Eur Heart J. 2021 Sep 21;42(36):3727-3738. doi: 10.1093/eurheartj/ehab560.

Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial
Butt, J.H., Docherty, K.F., Petrie, M.C., Schou, M., Kosiborod, M.N., … , Køber L.
JAMA Cardiol. 2021 Jun 1;6(6):678-689. doi: 10.1001/jamacardio.2021.0379.

Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction
Packer, M., McMurray, J.J.V.
Eur J Heart Fail. 2021 Jun;23(6):882-894. doi: 10.1002/ejhf.2149. Epub 2021 May 7.

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
Jhund, P.S., Ponikowski, P., Docherty, K.F., Gasparyan, S.B., Böhm, M., … , McMurray J.J.V.
Circulation. 2021 May 18;143(20):1962-1972. doi: 10.1161/CIRCULATIONAHA.121.053659. Epub 2021 Apr 9.

Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction
Berg, D.D., Jhund, P.S., Docherty, K.F., Murphy, S.A., Verma, S., … , Sabatine M.S.
JAMA Cardiol. 2021 May 1;6(5):499-507. doi: 10.1001/jamacardio.2020.7585.

Effect of dapagliflozin on anaemia in DAPA-HF
Docherty, K.F., Curtain, J.P., Anand, I.S., Bengtsson, O., Inzucchi, S.E., … , McMurray J.J.V.
Eur J Heart Fail. 2021 Apr;23(4):617-628. doi: 10.1002/ejhf.2132. Epub 2021 Mar 22.

Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial
Butt, J.H., Nicolau, J.C., Verma, S., Docherty, K.F., Petrie, M.C., … , Køber L.
Eur J Heart Fail. 2021 Apr;23(4):601-613. doi: 10.1002/ejhf.2124. Epub 2021 Mar 10.

Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF
Shen, L., Kristensen, S.L., Bengtsson, O., Böhm, M., de Boer, R.A., … , McMurray J.J.V.
JACC Heart Fail. 2021 Apr;9(4):254-264. doi: 10.1016/j.jchf.2020.11.009. Epub 2021 Feb 3.

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF
Dewan, P., Docherty, K.F., Bengtsson, O., de Boer, R.A., Desai, A.S., … , McMurray J.J.V.
Eur J Heart Fail. 2021 Apr;23(4):632-643. doi: 10.1002/ejhf.2083. Epub 2021 Jan 18.

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
McMurray, J.J.V., Solomon, S.D., Docherty, K.F., Jhund, P.S.
Eur Heart J. 2021 Mar 31;42(13):1199-1202. doi: 10.1093/eurheartj/ehz916.

How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine
McMurray, J.J.V., Packer, M.
Circulation. 2021 Mar 2;143(9):875-877. doi: 10.1161/CIRCULATIONAHA.120.052926. Epub 2020 Dec 30.

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
Inzucchi, S.E., Docherty, K.F., Køber, L., Kosiborod, M.N., Martinez, F.A., … , McMurray J.J.V.
Diabetes Care. 2021 Feb;44(2):586-594. doi: 10.2337/dc20-1675. Epub 2020 Dec 18.

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
Jhund, P.S., Solomon, S.D., Docherty, K.F., Heerspink, H.J.L., Anand, I.S., … , McMurray J.J.V.
Circulation. 2021 Jan 26;143(4):298-309. doi: 10.1161/CIRCULATIONAHA.120.050391. Epub 2020 Oct 12.

SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure
Docherty, K.F., McMurray, J.J.V.
Eur J Heart Fail. 2021 Jan;23(1):27-30. doi: 10.1002/ejhf.2075. Epub 2020 Dec 29.

Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?
Yeoh, S.E., Dewan, P., Jhund, P.S., Inzucchi, S.E., Køber, L., … , McMurray J.J.V.
Circ Heart Fail. 2020 Dec;13(12):e007879. doi: 10.1161/CIRCHEARTFAILURE.120.007879. Epub 2020 Nov 9.

Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy
Docherty, K.F., Jhund, P.S., Bengtsson, O., DeMets, D.L., Inzucchi, S.E., … , Ho D.
Diabetes Care. 2020 Nov;43(11):2878-2881. doi: 10.2337/dc20-1402. Epub 2020 Sep 2.

Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF
McEwan, P., Darlington, O., McMurray, J.J.V., Jhund, P.S., Docherty, K.F., … , Qin L.
Eur J Heart Fail. 2020 Nov;22(11):2147-2156. doi: 10.1002/ejhf.1978. Epub 2020 Sep 15.

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF
Docherty, K.F., Jhund, P.S., Anand, I., Bengtsson, O., Böhm, M., … , McMurray J.J.V.
Circulation. 2020 Oct 27;142(17):1623-1632. doi: 10.1161/CIRCULATIONAHA.120.047480. Epub 2020 Sep 4.

Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial
Solomon, S.D., Jhund, P.S., Claggett, B.L., Dewan, P., Køber, L., … , McMurray J.J.V.
JACC Heart Fail. 2020 Oct;8(10):811-818. doi: 10.1016/j.jchf.2020.04.008. Epub 2020 Jul 8.

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
Serenelli, M., Böhm, M., Inzucchi, S.E., Køber, L., Kosiborod, M.N., … , McMurray J.J.V.
Eur Heart J. 2020 Sep 21;41(36):3402-3418. doi: 10.1093/eurheartj/ehaa496.

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Jackson, A.M., Dewan, P., Anand, I.S., Bělohlávek, J., Bengtsson, O., … , McMurray J.J.V.
Circulation. 2020 Sep 15;142(11):1040-1054. doi: 10.1161/CIRCULATIONAHA.120.047077. Epub 2020 Jul 16.

Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
Vaduganathan, M., Claggett, B.L., Jhund, P.S., Cunningham, J.W., Pedro Ferreira, J., … , Solomon S.D.
Lancet. 2020 Jul 11;396(10244):121-128. doi: 10.1016/S0140-6736(20)30748-0. Epub 2020 May 21.

Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF
Dewan, P., Solomon, S.D., Jhund, P.S., Inzucchi, S.E., Køber, L., … , McMurray J.J.V.
Eur J Heart Fail. 2020 Jul;22(7):1247-1258. doi: 10.1002/ejhf.1867. Epub 2020 Jun 15.

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
Docherty, K.F., Jhund, P.S., Inzucchi, S.E., Køber, L., Kosiborod, M.N., … , McMurray J.J.V.
Eur Heart J. 2020 Jul 1;41(25):2379-2392. doi: 10.1093/eurheartj/ehaa183.

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Petrie, M.C., Verma, S., Docherty, K.F., Inzucchi, S.E., Anand, I., … , McMurray J.J.V.
JAMA. 2020 Apr 14;323(14):1353-1368. doi: 10.1001/jama.2020.1906.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply
McMurray, J.J.V., Docherty, K.F., Jhund, P.S.
N Engl J Med. 2020 Mar 5;382(10):973. doi: 10.1056/NEJMc1917241.

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial
Kosiborod, M.N., Jhund, P.S., Docherty, K.F., Diez, M., Petrie, M.C., … , McMurray J.J.V.
Circulation. 2020 Jan 14;141(2):90-99. doi: 10.1161/CIRCULATIONAHA.119.044138. Epub 2019 Nov 17.

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
Martinez, F.A., Serenelli, M., Nicolau, J.C., Petrie, M.C., Chiang, C-E., … , McMurray J.J.V.
Circulation. 2020 Jan 14;141(2):100-111. doi: 10.1161/CIRCULATIONAHA.119.044133. Epub 2019 Nov 17.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., Køber, L., Kosiborod, M.N., … , Langkilde A-M.
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.

The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics
McMurray, J.J.V., DeMets, D.L., Inzucchi, S.E., Køber, L., Kosiborod, M.N., … , Solomon S.D.
Eur J Heart Fail. 2019 Nov;21(11):1402-1411. doi: 10.1002/ejhf.1548. Epub 2019 Jul 15.

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
McMurray, J.J.V., DeMets, D.L., Inzucchi, S.E., Køber, L., Kosiborod, M.N., … , Solomon S.D.
Eur J Heart Fail. 2019 May;21(5):665-675. doi: 10.1002/ejhf.1432. Epub 2019 Mar 21.